Lubiprostone for the treatment of opioid-induced bowel dysfunction

Banny S. Wong, Michael Camilleri

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: Opioid-induced bowel dysfunction (OBD) is a prevalent condition that leads to reduced opioid use, human suffering and a high burden and cost on the healthcare system. Opioid-induced constipation (OIC) is the most troublesome aspect of OBD, for which standard laxatives are often ineffective. A major unmet need is effective and safe OIC treatment without inhibiting opioid analgesia or inducing opioid withdrawal symptoms. Recent data indicate that lubiprostone, a locally acting type 2 chloride channel activator, approved for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation, may be effective in treating OBD. Areas covered: The areas covered are: i) an overview of clinical trials of lubiprostone in the treatment of OBD based on peer-reviewed literature and congress materials from 2005 to 2010; and ii) an evaluation of the efficacy and potential mechanisms of action of lubiprostone in the treatment of OBD. Expert opinion: Lubiprostone has potential in treating OBD and deserves additional study. Lubiprostone's ability to promote fluid secretion locally at the apical membrane of intestinal epithelial cells ensures it does not provoke opioid withdrawal or compromise analgesia. Lubiprostone seems safe for long-term use in CIC patients, and a similar safety profile is anticipated in OBD.

Original languageEnglish (US)
Pages (from-to)983-990
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number6
DOIs
StatePublished - Apr 2011

Fingerprint

Opioid Analgesics
Constipation
Therapeutics
Lubiprostone
Analgesia
Fluids and Secretions
Laxatives
Substance Withdrawal Syndrome
Aptitude
Irritable Bowel Syndrome
Expert Testimony
Psychological Stress
Action Potentials
Meta-Analysis
Epithelial Cells
Delivery of Health Care
Safety
Costs and Cost Analysis

Keywords

  • analgesia
  • chloride channels
  • chronic pain
  • constipation
  • gastrointestinal motility
  • intestinal secretion
  • opioid

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Lubiprostone for the treatment of opioid-induced bowel dysfunction. / Wong, Banny S.; Camilleri, Michael.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 6, 04.2011, p. 983-990.

Research output: Contribution to journalArticle

@article{d11d3c2db55749bc8ac8fca7ee413f13,
title = "Lubiprostone for the treatment of opioid-induced bowel dysfunction",
abstract = "Introduction: Opioid-induced bowel dysfunction (OBD) is a prevalent condition that leads to reduced opioid use, human suffering and a high burden and cost on the healthcare system. Opioid-induced constipation (OIC) is the most troublesome aspect of OBD, for which standard laxatives are often ineffective. A major unmet need is effective and safe OIC treatment without inhibiting opioid analgesia or inducing opioid withdrawal symptoms. Recent data indicate that lubiprostone, a locally acting type 2 chloride channel activator, approved for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation, may be effective in treating OBD. Areas covered: The areas covered are: i) an overview of clinical trials of lubiprostone in the treatment of OBD based on peer-reviewed literature and congress materials from 2005 to 2010; and ii) an evaluation of the efficacy and potential mechanisms of action of lubiprostone in the treatment of OBD. Expert opinion: Lubiprostone has potential in treating OBD and deserves additional study. Lubiprostone's ability to promote fluid secretion locally at the apical membrane of intestinal epithelial cells ensures it does not provoke opioid withdrawal or compromise analgesia. Lubiprostone seems safe for long-term use in CIC patients, and a similar safety profile is anticipated in OBD.",
keywords = "analgesia, chloride channels, chronic pain, constipation, gastrointestinal motility, intestinal secretion, opioid",
author = "Wong, {Banny S.} and Michael Camilleri",
year = "2011",
month = "4",
doi = "10.1517/14656566.2011.566559",
language = "English (US)",
volume = "12",
pages = "983--990",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Lubiprostone for the treatment of opioid-induced bowel dysfunction

AU - Wong, Banny S.

AU - Camilleri, Michael

PY - 2011/4

Y1 - 2011/4

N2 - Introduction: Opioid-induced bowel dysfunction (OBD) is a prevalent condition that leads to reduced opioid use, human suffering and a high burden and cost on the healthcare system. Opioid-induced constipation (OIC) is the most troublesome aspect of OBD, for which standard laxatives are often ineffective. A major unmet need is effective and safe OIC treatment without inhibiting opioid analgesia or inducing opioid withdrawal symptoms. Recent data indicate that lubiprostone, a locally acting type 2 chloride channel activator, approved for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation, may be effective in treating OBD. Areas covered: The areas covered are: i) an overview of clinical trials of lubiprostone in the treatment of OBD based on peer-reviewed literature and congress materials from 2005 to 2010; and ii) an evaluation of the efficacy and potential mechanisms of action of lubiprostone in the treatment of OBD. Expert opinion: Lubiprostone has potential in treating OBD and deserves additional study. Lubiprostone's ability to promote fluid secretion locally at the apical membrane of intestinal epithelial cells ensures it does not provoke opioid withdrawal or compromise analgesia. Lubiprostone seems safe for long-term use in CIC patients, and a similar safety profile is anticipated in OBD.

AB - Introduction: Opioid-induced bowel dysfunction (OBD) is a prevalent condition that leads to reduced opioid use, human suffering and a high burden and cost on the healthcare system. Opioid-induced constipation (OIC) is the most troublesome aspect of OBD, for which standard laxatives are often ineffective. A major unmet need is effective and safe OIC treatment without inhibiting opioid analgesia or inducing opioid withdrawal symptoms. Recent data indicate that lubiprostone, a locally acting type 2 chloride channel activator, approved for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation, may be effective in treating OBD. Areas covered: The areas covered are: i) an overview of clinical trials of lubiprostone in the treatment of OBD based on peer-reviewed literature and congress materials from 2005 to 2010; and ii) an evaluation of the efficacy and potential mechanisms of action of lubiprostone in the treatment of OBD. Expert opinion: Lubiprostone has potential in treating OBD and deserves additional study. Lubiprostone's ability to promote fluid secretion locally at the apical membrane of intestinal epithelial cells ensures it does not provoke opioid withdrawal or compromise analgesia. Lubiprostone seems safe for long-term use in CIC patients, and a similar safety profile is anticipated in OBD.

KW - analgesia

KW - chloride channels

KW - chronic pain

KW - constipation

KW - gastrointestinal motility

KW - intestinal secretion

KW - opioid

UR - http://www.scopus.com/inward/record.url?scp=79952767341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952767341&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.566559

DO - 10.1517/14656566.2011.566559

M3 - Article

C2 - 21385112

AN - SCOPUS:79952767341

VL - 12

SP - 983

EP - 990

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -